Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened
- 7 July 2009
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 20 (10) , 1821-1835
Abstract
Objective To screen commonly used prescription drugs for possible carcinogenic effects. Methods In a large health care program we identified 105 commonly used drugs, not previously screened. Recipients were followed for up to 12½ years for incident cancer. Nested case–control analyses of 55 cancer sites and all combined included up to ten matched controls per case, with lag of at least 2 years between drug dispensing and cancer. Positive associations entailed a relative risk of 1.50, with p ≤ 0.01 and higher risk for three or more, than for one prescription. Evaluation included further analyses, searches of the literature, and clinical judgment. Results There were 101 associations of interest for 61 drugs. Sixty-six associations were judged to have involved substantial confounding. We found evidence that of the remaining 35, the following associations may not be due to chance: sulindac with gallbladder cancer and leukemia, hyoscyamine with nonHodgkin lymphoma, nortriptyline with esophageal and hepatic cancer, oxazepam with lung cancer, both fluoxetine and paroxetine with testicular cancer, hydrochlorothiazide with renal and lip cancer, and nifedipine with lip cancer. Conclusions These preliminary findings suggest that further studies are indicated regarding sulindac, hyoscyamine, nortriptyline, oxazepam, fluoxetine, paroxetine, hydrochlorothiazide, and nifedipine.Keywords
This publication has 50 references indexed in Scilit:
- Use of photosensitising diuretics and risk of skin cancer: a population-based case–control studyBritish Journal of Cancer, 2008
- Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipientsPharmacoepidemiology and Drug Safety, 2007
- Cohort study of COX‐1 and COX‐2 expression in canine rectal and bladder tumoursJournal of Small Animal Practice, 2006
- Breast cancer risk in a large cohort of female antidepressant medication usersCancer Letters, 2005
- Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancerJournal of Clinical Epidemiology, 2003
- Fertility and General Reproduction Studies in Rats with the HMG-CoA Reductase Inhibitor, AtorvastatinFundamental and Applied Toxicology, 1996
- Prescription drug screening for subsequent carcinogenicityPharmacoepidemiology and Drug Safety, 1995
- A toxicological review of beta-adrenergic blockersFundamental and Applied Toxicology, 1986
- APLASTIC ANEMIA AND ACUTE LEUKEMIA: A POSSIBLE RELATIONSHIP WITH SULINDAC THERAPY?Australian and New Zealand Journal of Medicine, 1985
- SULINDAC-INDUCED BONE MARROW TOXICITYThe Lancet, 1980